Published in Can J Gastroenterol on May 01, 2009
When can patients with potentially life-threatening adverse effects be rechallenged with clozapine? A systematic review of the published literature. Schizophr Res (2011) 1.15
Re: Recent case report of clozapine-induced acute hepatic failure. Can J Gastroenterol (2010) 0.82
Eosinophilia, pleural effusion, hepatitis, and jaundice occurring early in clozapine treatment. Clin Psychopharmacol Neurosci (2013) 0.79
Hepatotoxicity induced by clozapine: a case report and review of literature. Neuropsychiatr Dis Treat (2014) 0.75
Psychotropic drugs and liver disease: A critical review of pharmacokinetics and liver toxicity. World J Gastrointest Pharmacol Ther (2017) 0.75
Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med (2002) 11.38
Fatal acute fulminant liver failure due to clozapine: a case report and review of clozapine-induced hepatotoxicity. Gastroenterology (1997) 1.44
Hepatotoxicity of clozapine. J Clin Psychopharmacol (1997) 1.07
Clozapine-induced toxic hepatitis. Am J Psychiatry (1995) 1.01
Clozapine-induced intestinal occlusion: a serious side effect. Acta Biomed (2007) 0.90
Relevance of liver enzyme elevations with four different neuroleptics: a retrospective review of 7,263 treatment courses. J Clin Psychopharmacol (2001) 0.89
Acute onset of ascites with clozapine-induced hepatitis. Intern Med J (2007) 0.89
Dystonia and drug-induced hepatitis in a patient treated with clozapine. Am J Psychiatry (1995) 0.88
Hepatic encephalopathy associated with combined clozapine and divalproex sodium treatment. J Clin Psychopharmacol (1997) 0.86
[Liver cell necrosis during administration of clozapine]. Ned Tijdschr Geneeskd (1994) 0.85
Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med (2011) 16.93
Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med (2013) 8.49
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med (2014) 6.31
Asian ethnicity-related differences in gastric cancer presentation and outcome among patients treated at a canadian cancer center. J Clin Oncol (2003) 2.17
Liver injury associated with the beta-interferons for MS: a comparison between the three products. Neurology (2004) 2.16
Choledochal cysts: part 1 of 3: classification and pathogenesis. Can J Surg (2009) 1.91
Adult liver transplant survey: policies towards eligibility criteria in Canada and the United States 2007. Liver Int (2008) 1.77
Exploring the psychological effects of deceased organ donation on the families of the organ donors. Clin Transplant (2008) 1.75
Granulomatous hepatitis associated with etanercept therapy. J Rheumatol (2008) 1.56
Severe desflurane hepatotoxicity after colon surgery in an elderly patient. Can J Anaesth (2005) 1.55
Pregnancy and sexual function in liver transplantation. J Hepatol (2008) 1.49
Cross-sectional study of hepatitis B awareness among Chinese and Southeast Asian Canadians in the Vancouver-Richmond community. Can J Gastroenterol (2005) 1.47
Line sepsis in home parenteral nutrition patients: are there socioeconomic risk factors? A Canadian study. JPEN J Parenter Enteral Nutr (2005) 1.46
Spatulated end-to-end bile duct reconstruction in orthotopic liver transplantation. Clin Transplant (2007) 1.39
Fatal reactivation of hepatitis B post-chemotherapy for lymphoma in a hepatitis B surface antigen-negative, hepatitis B core antibody-positive patient: potential implications for future prophylaxis recommendations. Leuk Lymphoma (2005) 1.21
Choledochal cysts. Part 3 of 3: management. Can J Surg (2010) 1.21
Patient preference and willingness to pay for transient elastography versus liver biopsy: A perspective from British Columbia. Can J Gastroenterol Hepatol (2015) 1.19
Gastric polyps in patients with portal hypertension. Eur J Gastroenterol Hepatol (2011) 1.16
Percutaneous liver biopsy practice patterns among Canadian hepatologists. Can J Gastroenterol (2013) 1.15
Comparison of acoustic radiation force impulse imaging (ARFI) to liver biopsy histologic scores in the evaluation of chronic liver disease: A pilot study. Ann Hepatol (2010) 1.14
Health utilities and psychometric quality of life in patients with early- and late-stage hepatitis C virus infection. J Gastroenterol Hepatol (2012) 1.13
Sustained responders have better quality of life and productivity compared with treatment failures long after antiviral therapy for hepatitis C. Am J Gastroenterol (2009) 1.10
Does this patient with liver disease have cirrhosis? JAMA (2012) 1.09
Peginterferon alpha-2a (40kD) [Pegasys] improves HR-QOL outcomes compared with unmodified interferon alpha-2a [Roferon-A]: in patients with chronic hepatitis C. Pharmacoeconomics (2003) 1.05
A review of drug interactions with boceprevir and telaprevir: implications for HIV and transplant patients. Ann Hepatol (2012) 1.05
Choledochal cysts: part 2 of 3: Diagnosis. Can J Surg (2009) 1.03
Acute fatty liver of pregnancy. Can J Gastroenterol (2006) 1.03
Post-liver transplantation diabetes mellitus: an association with hepatitis C. Liver Transpl (2002) 1.01
Hepatitis C drugs: the end of the pegylated interferon era and the emergence of all-oral interferon-free antiviral regimens: a concise review. Can J Gastroenterol Hepatol (2014) 1.00
Primary hepatic neuroendocrine tumour requiring live donor liver transplantation: case report and concise review. Ann Hepatol (2012) 0.99
Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl (2005) 0.98
Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int (2005) 0.98
Late acute rejection after liver transplantation: the Western Canada experience. Liver Transpl (2002) 0.96
Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology (2008) 0.95
Predictors of relapse to significant alcohol drinking after liver transplantation. Can J Gastroenterol (2010) 0.94
Liver transplantation for hepatic epithelioid hemangioendothelioma: the Canadian multicentre experience. Can J Gastroenterol (2008) 0.93
Parvovirus B19 in an immunocompetent adult patient with acute liver failure: an underdiagnosed cause of acute non-A-E viral hepatitis. Can J Gastroenterol (2005) 0.93
Post-liver transplant Crohn's disease: graft tolerance but not self-tolerance? Dig Dis Sci (2002) 0.93
Retinal vein thrombosis associated with pegylated-interferon and ribavirin combination therapy for chronic hepatitis C. World J Gastroenterol (2006) 0.92
Hypovitaminosis D in adults with inflammatory bowel disease: potential role of ethnicity. Dig Dis Sci (2012) 0.91
Outcomes of peginterferon alpha-2a and ribavirin hepatitis C therapy in Aboriginal Canadians. Can J Gastroenterol (2008) 0.91
Review of boceprevir and telaprevir for the treatment of chronic hepatitis C. Can J Gastroenterol (2012) 0.91
Late acute celiac and hepatic artery thrombosis with portal vein thrombosis resulting in hepatic infarction 12 years post orthotopic liver transplantation. Ann Hepatol (2009) 0.91
Balapiravir plus peginterferon alfa-2a (40KD)/ribavirin in a randomized trial of hepatitis C genotype 1 patients. Ann Hepatol (2011) 0.90
Iron overload disorders: treatment options for patients refractory to or intolerant of phlebotomy. Pharmacotherapy (2008) 0.89
Treatment of chronic hepatitis C in Canadian prison inmates. Can J Gastroenterol (2005) 0.89
Parvovirus B19 induced hepatic failure in an adult requiring liver transplantation. World J Gastroenterol (2009) 0.88
Effects of upper extremity exercise training on peak aerobic and anaerobic fitness in patients after transplantation. Am J Cardiol (2004) 0.87
Hepatology and the Canadian gastroenterologist: interest, attitudes and patterns of practice: results of a national survey from the Canadian Association of Gastroenterology. Can J Gastroenterol (2003) 0.87
A phase 2 study to evaluate the antiviral activity, safety, and pharmacokinetics of recombinant human albumin-interferon alfa fusion protein in genotype 1 chronic hepatitis C patients. J Hepatol (2006) 0.87
Retrospective review of pediatric and adult autoimmune hepatitis in two quaternary care centres in British Columbia: increased prevalence seen in British Columbia's First Nations community. Can J Gastroenterol (2007) 0.86
Spontaneous clearance of hepatitis C infection post-liver transplant: A rare but real phenomenon? A case report and review of the literature. Ann Hepatol (2010) 0.86
Transient improvement of acquired hepatocerebral degeneration with parkinsonian symptoms after failed liver transplant: case report and literature review. Exp Clin Transplant (2011) 0.85
Fatal postlymphoma chemotherapy hepatitis B reactivation secondary to the emergence of a YMDD mutant strain with lamivudine resistance in a noncirrhotic patient. Am J Hematol (2006) 0.85
Transient elastography in Canada: Current state and future directions. Can J Gastroenterol Hepatol (2015) 0.85
Does cirrhosis affect quality of life in hepatitis C virus-infected patients? Liver Int (2009) 0.84
In a 'real-world', clinic-based community setting, sorafenib dose of 400 mg/day is as effective as standard dose of 800 mg/day in patients with advanced hepatocellular carcimona, with better tolerance and similar survival. Can J Gastroenterol (2013) 0.83
First successful treatment of post-liver transplant hepatitis C fibrosing cholestatic hepatitis with boceprevir, peginterferon and ribavirin in a pre-transplant null responder. Ann Hepatol (2013) 0.83
Ethnic variation in the annual rates of adult inflammatory bowel disease in hospitalized patients in Vancouver, British Columbia. Can J Gastroenterol (2011) 0.83
Response to endoscopic therapy for biliary anastomotic strictures in deceased versus living donor liver transplantation. Hepatobiliary Pancreat Dis Int (2013) 0.83
Liver transplant candidacy unsuitability: a review of the British Columbia experience. Can J Gastroenterol (2006) 0.82
Poor prediction of the glomerular filtration rate using current formulas in de novo liver transplant patients. Transplantation (2006) 0.82
Recurrent ectopic pancreatitis of the jejunum and mesentery over a 30-year period. Hepatobiliary Pancreat Dis Int (2011) 0.82
Utilization of a liver allograft from a hepatitis B surface antigen positive donor. Transplantation (2006) 0.81
Fatal hepatitis C associated fibrosing cholestatic hepatitis as a complication of cyclophosphamide and corticosteroid treatment of active glomerulonephritis. Ann Hepatol (2007) 0.81
Sexual health after orthotopic liver transplantation. Liver Transpl (2006) 0.81
Carnitine deficiency presenting with encephalopathy and hyperammonemia in a patient receiving chronic enteral tube feeding: a case report. J Med Case Rep (2012) 0.81
Abdominal pain as the initial and sole clinical presenting feature of systemic lupus erythematosus. Can J Gastroenterol (2003) 0.81
A rare case of isolated duodenal metastases from hepatocellular carcinoma associated with p53 and ki-67 expression: a case report. Cases J (2009) 0.81
Genome-wide association study to characterize serum bilirubin elevations in patients with HCV treated with GS-9256, an HCV NS3 serine protease inhibitor. Antivir Ther (2014) 0.80
The use of budesonide in the treatment of autoimmune hepatitis in Canada. Can J Gastroenterol (2008) 0.80
The use of sildenafil to treat portopulmonary hypertension prior to liver transplantation. Ann Hepatol (2009) 0.80
Surgical morbidity in severely obese liver transplant recipients - a single Canadian Centre Experience. Ann Hepatol (2009) 0.80
Familial adenomatous polyposis-rendering a diagnosis based on recognition of an unusual primary thyroid neoplasm. Case Rep Med (2011) 0.79
Subcutaneous administration of hepatitis B immune globulin in combination with lamivudine following orthotopic liver transplantation: effective prophylaxis against recurrence. Clin Transplant (2006) 0.79
Efficacy of maintenance subcutaneous hepatitis B immune globulin (HBIG) post-transplant for prophylaxis against hepatitis B recurrence. Ann Hepatol (2010) 0.79
Expression of integrin-linked kinase is not a useful prognostic marker in resected hepatocellular cancer. Anticancer Res (2008) 0.79
Sofosbuvir-Based Antiviral Therapy Is Highly Effective In Recurrent Hepatitis C in Liver Transplant Recipients: Canadian Multicenter "Real-Life" Experience. Transplantation (2016) 0.79
Screening, detecting and enhancing the yield of previously undiagnosed hepatitis B and C in patients with acute medical admissions to hospital: a pilot project undertaken at the Vancouver General Hospital. Can J Gastroenterol Hepatol (2014) 0.79
Non-invasive assessment of liver fibrosis using ARFI with pathological correlation, a prospective study. Ann Hepatol (2013) 0.78
Safety and antiviral activity of albinterferon alfa-2b dosed every four weeks in genotype 2/3 chronic hepatitis C patients. Clin Gastroenterol Hepatol (2008) 0.78
Patient time costs and out-of-pocket costs in hepatitis C. Liver Int (2012) 0.78
Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C. Liver Int (2009) 0.78
Treatment issues surrounding hepatitis C in renal transplantation: a review. Ann Hepatol (2011) 0.78
Use of hematopoietic growth factors as adjuvant therapy for anemia and neutropenia in the treatment of hepatitis C. Ann Pharmacother (2007) 0.78
Racial differences between solid organ transplant donors and recipients in British Columbia 2005-2009: a follow-up study since the last analysis in 1993-1997. Transplantation (2013) 0.78
Hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Ann Hepatol (2009) 0.78
Liver transplantation for alcoholic liver disease among Canadian transplant centres: a national study. Can J Gastroenterol (2013) 0.78
The prevalence of gestational diabetes mellitus and glucose abnormalities in pregnant women with hepatitis C virus infection in British Columbia. J Obstet Gynaecol Can (2010) 0.77
Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study. Exp Clin Transplant (2016) 0.77
Echinococcus presenting as painless jaundice. Can J Gastroenterol (2012) 0.77
Hepatitis C infection among pregnant women in British Columbia: reported prevalence and critical appraisal of current prenatal screening methods. Can J Public Health (2011) 0.77
Regression of cirrhosis associated with hepatitis B e (HBe) antigen-negative chronic hepatitis B infection with prolonged lamivudine therapy. Eur J Gastroenterol Hepatol (2004) 0.77
Assessing medication adherence in solid-organ transplant recipients. Exp Clin Transplant (2013) 0.77
Methadone maintenance therapy in liver transplantation. Prog Transplant (2010) 0.76
Severe cholestasis due to adalimumab in a Crohn's disease patient. World J Hepatol (2013) 0.76
A concise review of hepatitis C in heart and lung transplantation. Can J Gastroenterol (2011) 0.76
Dynamics of interferon-specific gene expression in peripheral blood of interferon alfa-naïve patients with genotype 1 chronic hepatitis C infection treated with albumin-interferon alfa. Hepatol Res (2006) 0.76